Expansion footprint Urgent opportunity to engage with United Therapeutics on co-located facilities and xenotransplantation initiatives, given recent investments in Merrimack NH, Lexington MA, Stewartville MN, and Rochester NY, as well as planned facility expansions to support gene-edited pig organ production.

Public benefit positioning Leverage United Therapeutics unique public benefit corporate status to align value-based partnerships, patient-centric programs, and social impact collaborations that can attract government grants, non-dilutive funding, and responsible sourcing opportunities.

Transplant tech play Target collaborations around organ printing, gene editing, and designated pathogen-free facilities to offer specialty manufacturing, quality systems, and supply chain services aligned with their xenotransplantation and organ-biology initiatives.

Digital productivity Cross-sell enterprise tech services and consulting leveraging their listed tech stack (iCIMS, Salesforce, SAP BI, Azure, Power Platform) to optimize talent, CRM, data analytics, and operational efficiency across expanding sites.

Strategic partnerships Position for partnerships with manufacturing facilities, farmland and real estate acquisitions, and campus development by offering utilities, logistics, and regulatory-compliant build-outs to accelerate site readiness and scale production capabilities.